Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Bullish Bayer Highlights Four Future Blockbusters

New Growth Drivers Could Have €12bn Peak Sales

Jan 11 2023

• By Kevin Grogan

Bayer Pharma AG, Administration and laboratory buildings of Bayer HealthCare Pharmaceuticals in Berlin-Wedding on June 14, 2017, Germany - Image — • Source: Bayer

Related Content

Bayer Backs Hot Flashes Drug For Blockbuster Status

Nov 09 2021

Bayer Goes All In With Asundexian And Pulls Two Other Factor XIa Projects

Nov 08 2022

High-Dose Eylea’s Improved Durability Could Protect Regeneron’s Market Share

Sep 09 2022

Bayer Outlines Asundexian Phase III Plan, Hoping To Prove Safety Benefit Over Eliquis

Aug 29 2022

Menopause Drug A Priority For Astellas

Aug 18 2022

Related Companies

Bayer AG

Bristol Myers Squibb Company

Johnson & Johnson

KaNDy Therapeutics Ltd.

Astellas Pharma, Inc.

Regeneron Pharmaceuticals, Inc.

Additional Topics

Business Strategies Clinical Trials Commercial Launches Cardiovascular Cancer BioPharmaceutical

More from Strategy

More from Business

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window